A Second Indication on the Same Headband: Ceribell, Delirium and the Economics of ICU Neuromonitoring
Dr. Dereck Mush, MD, MBA
Ceribell
Point of care electroencephalography systems for rapid seizure detection.
What they do
The company manufactures a simplified headband and diagnostic platform that enables rapid bedside detection of non-convulsive status epilepticus. Emergency departments and intensive care units purchase this system to make fast, informed decisions regarding brain monitoring. On September 30, 2026 Ceribell announced FDA 510(k) clearance for new software adding Alpha-Delta Ratio and Relative Alpha trending, burst suppression monitoring and amplitude-integrated EEG, with no age restriction; the features are expected via software update in the first half of 2027. On November 2, 2026 Ceribell announced commercial launch of its Delirium Monitoring Solution following FDA 510(k) clearance on December 9, 2025. It supports clinician delirium screening and monitoring on the seizure-monitoring platform and headband. Ceribell trades on Nasdaq as CBLL. CMS NTAP is up to $2,171 per eligible Medicare case from October 1, 2026, not a guaranteed payment for every case.
People in this update
The record
- Vertical
- Medical Devices
- Sub-segment
- Point of care diagnostics
- Product type
- Device
- Stage
- Public
- Headquarters
- Sunnyvale, USA
- Region
- North America
- Founded
- 2014
- Total funding
- $110M raised
Notable investors: The Rise Fund, Tee Grove Ventures, Redmile Group.
Also in Medical Devices
Related on The Signal
Dr. Dereck Mush, MD, MBA
Mobile Optical Diagnostics: Ending the Multibillion-Dollar Emergency Vertigo Workup
Dr. Dereck Mush, MD, MBA
Point-of-Care Ultrasound Is the Quiet Revolution in Diagnostics
Dr. Dereck Mush, MD, MBA
Decentralizing Syndromic PCR: The Point-of-Care Molecular Margin War
Dr. Dereck Mush, MD, MBA